+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cerebrovascular Diseases Treatment Research and Forecast 2018-2023

  • ID: 4700801
  • Report
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Aldagen Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Penumbra Inc
  • MORE
Cerebrovascular diseases are caused due to the variety of medical conditions that affect or damage the arteries that supply oxygen and nutrients to the brain. This is majorly caused by ischemic stroke and hemorrhagic stroke. It can be diagnosed using various tools and techniques such as cerebral angiography, carotid duplex, computed tomography, electroencephalogram and other diagnosis procedure. The diseases can be treated by medication such as antiplatelets (aspirin, clopidogrel), blood thinners (heparin, warfarin), antihypertensives (ACE inhibitors, beta blockers), anti-diabetic medications and surgical procedures such as endovascular surgery, vascular surgery. The increasing inherited congenital diseases and the rising aging population is major growth fuelling factor for this market. There are various hospitals and practitioners who are adopting hormone replacement therapy which can further cause the major stroke, and the unhealthy eating habits are leading to high cholesterol level that can lead to the adoption of such treatment.

The high cost of cerebrovascular diseases treatment and the lack of availability of generics are the major factors that can threaten the market growth of such treatment. There are still some healthcare organization and diagnostic centers that do not have such treatment resources and equipment to treat the patient. However, increasing healthcare expenditure and the adoption of minimally invasive treatment can create more opportunity in the future for this market. Increasing prevalence of diabetes and the increasing awareness of emerging therapies can contribute to the prominent growth of cerebrovascular diseases treatment in the future.

Geographically market is divided into North America, Europe, Asia Pacific and Rest of the World. North America region is dominating the overall global cerebrovascular diseases treatment market. The growth in this region is driven by the increasing awareness of emerging technologies and the excessive consumption of alcohol and tobacco. Moreover, the lack of exercise and the changing eating habits which are leading to higher cholesterol and risk of stroke is the driving factor for cerebrovascular diseases treatment market in the Asia Pacific region.

There are many companies which are contributing in cerebrovascular diseases treatment market such as Actelion Pharmaceuticals Ltd., Bayer AG, Amgen Inc., Pfizer Inc., Portola Pharmaceuticals, Inc., Sanofi Takeda Pharmaceutical Company Limited, Sihuan Pharmaceutical Holdings Group Ltd., and so on. The companies are working on developing innovative cerebrovascular diseases treatment and therapies and research and innovation. In addition, they are involved in activities such as expansion M&A, finding a new market or innovate in their core competency in order to expand individual market share.

Research methodology

The market study of Cerebrovascular Diseases Treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the OICA, OECD, WHO and others
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.
The Report is intended for the cerebrovascular diseases drug manufacturer, Investing companies, emerging companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

Global Cerebrovascular Diseases t market is segmented on the basis of regional outlook and following segments:

1. Global Cerebrovascular Diseases Market Research and Analysis, By Type of Stroke

2. Global Cerebrovascular Diseases Market Research and Analysis, By Diagnosis

3. Global Cerebrovascular Diseases Market Research and Analysis, By Treatment

4. Global Cerebrovascular Diseases Market Research and Analysis, By End User

The Report Covers::
  • Comprehensive research methodology of Global Cerebrovascular Diseases
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the
  • Global Cerebrovascular Diseases Market.
  • Insights about market determinants which are stimulating the Global Cerebrovascular Diseases
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aldagen Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Penumbra Inc
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Market Definition
2.1. Patent Analysis
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations
2.3.1. United States
2.3.2. European Union
2.3.3. China
2.3.4. Japan
2.3.5. India

3. Market Determinant
3.1. Motivators
3.1.1. Increasing Cases of Stroke Due to Hormone Replacement Therapy
3.1.2. Rising Cholesterol Level Coupled with Aging Population
3.1.3. Rising Inherited Congenital Disease
3.1.4. Sedentary Lifestyle Such as Smoking and Tobacco and Alcohol Consumption
3.1.5. Increasing Diabetic Cases
3.2. Restraints
3.2.1. Lack of Availability of Generics
3.2.2. High Cost of Treatment
3.3. Opportunities
3.3.1. Increasing Healthcare Expenditure and Improvement in Healthcare Infrastructure
3.3.2. Adoption of Minimally Invasive Treatment

4. Market Segmentation
4.1. Global Cerebrovascular Disease Treatment Market, By Type of Stroke
4.1.1. Ischemic
4.1.2. Haemorrhagic
4.2. Global Cerebrovascular Disease Treatment Market, By Diagnosis
4.2.1. Cerebral Angiography
4.2.2. Carotid Duplex
4.2.3. Computed Tomography
4.2.4. Electroencephalogram
4.3. Global Cerebrovascular Disease Treatment Market, By Treatment
4.3.1. Medication
4.3.1.1. Antiplatelets
4.3.1.2. Antihypertensives
4.3.1.3. Others
4.3.2. Surgical Procedure
4.3.2.1. Endovascular Surgery
4.3.2.2. Vascular Surgery
4.3.2.3. Others
4.4. Global Cerebrovascular Disease Treatment Market, By End User
4.4.1. Hospitals
4.4.2. Surgical Clinics
4.4.3. Research Institutions

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Actelion Pharmaceuticals Ltd.
7.2. Aldagen Inc.
7.3. Amgen Inc.
7.4. AstraZeneca plc
7.5. Bayer AG
7.6. Boehringer Ingelheim International GmbH
7.7. Bristol-Myers Squibb
7.8. Daiichi Sankyo Company, Limited
7.9. F. Hoffmann-La Roche AG
7.10. GlaxoSmithKline plc
7.11. Johnson & Johnson
7.12. Merck & Co., Inc.
7.13. Novartis International AG
7.14. Penumbra Inc
7.15. Pfizer Inc.
7.16. Portola Pharmaceuticals, Inc.
7.17. Sangamo Therapeutics, Inc.
7.18. Sanofi SA
7.19. Sihuan Pharmaceutical Holdings Group Ltd
7.20. Takeda Pharmaceutical Company Limited
7.21. Tianda Pharmaceuticals Limited
7.22. United Therapeutics Corporation
7.23. Zocere, Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actelion Pharmaceuticals Ltd.
  • Aldagen Inc.
  • Amgen Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ag
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International Ag
  • Penumbra Inc
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi Sa
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Takeda Pharmaceutical Company Limited
  • Tianda Pharmaceuticals Limited
  • United Therapeutics Corporation
  • Zocere, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll